SCHEMBL4897265

SCHEMBL4897265

COC(=O)c1ccc(-c2cn(C3CC3)c(=O)n2Cc2ccc(CP(=O)(OF)OF)c(Br)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.37
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MCHR1 Q99705 1/20 0.34
CNR2 P34972 1/20 0.34
MAPK8 P45983 1/20 0.33
CHKA P35790 1/20 0.33
CHRM4 P08173 1/20 0.33
USP2 O75604 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CCR6 P51684 1/20 0.32
HKDC1 Q2TB90 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898720 0.91 MAPK8 (0.36) MAPK10HIF1AALDH1A1CNR2MAPK8
SCHEMBL4891960 0.91 GCGR (0.34) MAPK10ALDH1A1MCHR1HDAC1HDAC2
SCHEMBL4891992 0.88 MAPK10 (0.39) MAPK10HIF1AALDH1A1MCHR1MAPK8
SCHEMBL4900432 0.87 NR1H4 (0.31) CNR2HDAC1HDAC2HDAC6
SCHEMBL4890554 0.87 MAPK10 (0.38) MAPK10HIF1AALDH1A1MCHR1MAPK8
SCHEMBL4899314 0.85 MAPK10 (0.37) MAPK10HIF1AALDH1A1MCHR1MAPK8
SCHEMBL4894087 0.85 PPARA (0.36)
SCHEMBL4893914 0.85 MAPK10 (0.36) MAPK10HIF1AALDH1A1NPC1MCHR1
SCHEMBL4900023 0.85 MAPK10 (0.40) MAPK10HIF1AALDH1A1MAPK8USP2
SCHEMBL4901331 0.85 MAPK10 (0.42) MAPK10HIF1AALDH1A1CNR2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS MAPK10 656/4885HIF1A 1650/4885ALDH1A1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.